Replay available

Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call

Lineage Cell Therapeutics, Inc. (AMEX: LCTX) Q3 2025 earnings conference call, held 2025-11-06. Replay captured from the company's public earnings webcast.

Thu, November 6, 2025 at 4:30 PMendedReplay
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Iona Hohn

Head of Investor Relations

Brian Culley

Chief Executive Officer

Jill Howe

Chief Financial Officer

Mayank Mantani

Analyst, B. Riley Securities

Joe Van Guinness

Analyst, H.C. Wainwright

Boris Pieker

Analyst, Titan Partners

Sean McCutcheon

Analyst, Raymond James

Albert Lowe

Analyst

Replay transcript excerpt

Welcome to the Lineage Cell Therapeutics 3rd Quarter 2025 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the Investor section of Lineage's website at www.lineagesell.com. This call is subject to copyright and is the property of Lineage. And the recordings, reproductions, or transmissions of this call without the express written consent of Lineage are strictly prohibited. As a reminder, today's call is being recorded. I would now like to introduce your host for today's call, Iona Hohn, Head of Investor Relations at Lineage. Ms. Hohn, please go ahead. Thank you, Angela. Good afternoon, and thank you for joining us. A press release reporting our third quarter 2025 financial results was issued earlier today, November 6, 2025, and can be found on the Investors section of our website. Please note that today's remarks and responses to your questions reflect management's views as of today only and will contain forward-looking statements within the meaning of federal securities laws. Statements made during this discussion that are not statements of historical fact should be considered forward-looking statements. which are subject to significant risks and uncertainties. The company's actual results or performance may differ materially from the expectations indicated by such forward-looking statements. For a discussion of certain factors that could cause the company's results or performance to differ, we refer you to the forward-looking statement sections in today's press release and in the company's SEC filings, including its most recent annual report on Form 10-K and in subsequent SEC filings. We caution you not to place undue reliance on any forward-looking statements, which speak only as of today and ...

More from Lineage Cell Therapeutics, Inc.